The Lymphoma Research Foundation (LRF) is proud to be a national thought leader in the area of public policy, advocating for polices and legislation that will improve the lives of people with lymphoma and CLL. The Foundation leads efforts to…
New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This…
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and…
As part of the Lymphoma Research Foundation’s ongoing efforts in support of early career lymphoma researchers, the Foundation was proud to host a Biden Cancer Community Summit on September 21, 2018. The Summit, one of several held across the country…
The Lymphoma Research Foundation extends its heartfelt condolences to the family, loved ones and colleagues of Paul Allen. Mr. Allen contributed greatly to science, philanthropy and business and was committed to improving people’s lives and strengthening communities around the world. Our…
The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and support services – held its Annual Gala…
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after…
Since 2011, the Lymphoma Research Foundation (LRF) has been a pioneer in shedding a “light” on lymphoma during September, recognized each year by the United States Congress as national Blood Cancer Awareness Month (BCAM), with LRF’s trademarked Light it Red for…
To celebrate his outstanding achievements in lymphoma research and clinical care, his dedication to lymphoma patients and their loved ones, and his longstanding support of the Lymphoma Research Foundation (LRF), LRF will honor John P. Leonard, MD at its 2018…
New York, NY (August 27, 2018) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the treatment of adult patients with Waldenström macroglobulinemia (WM). This approval represents the…